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Abstract
Background: Although significant response time deficits (both reaction time and movement time)
have been identified in numerous studies of patients with Parkinson's disease (PD), few attempts
have been made to evaluate the use of these measures in screening for PD.
Methods: Receiver operator characteristic curves were used to identify cutoff scores for a unit-
weighted composite of two choice response tasks in a sample of 40 patients and 40 healthy
participants. These scores were then cross-validated in an independent sample of 20 patients and
20 healthy participants.
Results: The unit-weighted movement time composite demonstrated high sensitivity (90%) and
specificity (90%) in the identification of PD. Movement time was also significantly correlated (r =
0.59, p < 0.025) with the motor score of the Unified Parkinson's Disease Rating Scale (UPDRS).
Conclusions: Measures of chronometric speed, assessed without the use of biomechanically
complex movements, have a potential role in screening for PD. Furthermore, the significant
correlation between movement time and UPDRS motor score suggests that movement time may
be useful in the quantification of PD severity.
Background
The success of dopaminergic interventions in the treat-
ment of Parkinson's disease (PD) symptoms has been sig-
nificant. Nevertheless, a misdiagnosis of PD can cause
psychological trauma and unnecessarily expose patients
to PD drugs. Additionally, as new, and possibly neuropro-
tective, drugs become available for the treatment of PD,
early and accurate diagnosis will become increasingly
important. As the diagnosis of PD is usually based on sub-
jective clinical assessment of overt symptomatology [1],
the need for an objective and reproducible battery of diag-
nostic tests is great. Medical imagery offers some hope for
the objective diagnosis of PD (e.g. 18F-dopa positron
emission tomography [2]), but these techniques tend to
be expensive, and inaccessible to patients living in remote
areas. What is truly needed is a low-cost objective test bat-
tery that might be used in situations where (a) movement
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noses, and (b) medical imaging is inaccessible.
Montgomery et al. [3,4] have published one of the better
known objective PD batteries, incorporating measures of
motor performance, olfaction, and mood. The aggregate
of all subtests of this battery has demonstrated good diag-
nostic properties, with a sensitivity of approximately 70%,
and a specificity of approximately 90%. Given that the pri-
mary symptoms of PD are motoric [1], however, it is inter-
esting to note that the sensitivity of the motor task in this
PD battery is approximately 50% [3,4], indicating that
diagnoses based solely on this subtest are not much better
than chance. As the predictive power of a battery increases
with the addition of each valid and independent subtest,
it is important to evaluate motor performance paradigms
that may produce better predictive validity.
The global slowing that is consistently demonstrated by
PD patients suggests that measures of cognitive or motor
speed are logical methods for obtaining quantitative
measurements of PD severity. As reaction time (RT) and
movement time (MT) have repeatedly been demonstrated
to show substantive and significant deficits in PD popula-
tions (for a review of this literature, see Gauntlett-Gilbert
et al. [5]), these indicators are (by definition) capable of
distinguishing individuals with PD from healthy partici-
pants. Despite this fact, however, the motor subtest of the
PD battery described by Montgomery et al. [3,4] remains
the only significant attempt at evaluating diagnostic accu-
racy with these chronometric indicators. Although this
subtest measures both RT and MT, the task is performed
in a biomechanically complicated fashion that requires
the participant to move his/her hand in an arc (i.e. wrist
flexion and extension) to aim at LED targets. This test
assesses both rigidity and bradykinesia within the same
task – and while this is a conceptually defensible measure-
ment decision, the resulting inter-subject variability may
overwhelm group differences, and confound diagnostic
accuracy. It is, therefore, worth examining the extent to
which a simpler paradigm might be used to distinguish
PD patients from healthy participants.
The goal of this study, therefore, is to evaluate the diag-
nostic properties of a choice reaction time task that uses a
simple external response console (i.e. a "button box"),
similar to other similar response time tasks extant within
the PD literature.
Methods
Two independent samples were drawn for this study, the
first consisting of 40 PD patients (Age: M = 62.13, SD =
9.59) and 40 healthy participants (Age: M = 65.02, SD =
8.84), and the second consisting of 20 PD patients (Age:
M = 64.50, SD = 10.88) and 20 healthy participants (Age:
M = 62.65, SD = 12.02). To ensure that no baseline ability
differences existed between groups, Wechsler Adult Intel-
ligence Scale (WAIS) full scale IQ estimates were com-
puted for all participants, using the National Adult
Reading Test (NART) [6]. No significant age or IQ differ-
ences were identified between patients and controls, in
either sample. During the course of testing, patients were
also assessed by an experienced clinician (using the motor
subscale of the Unified Parkinson's Disease Rating Scale;
UPDRS), to determine the severity of their motor symp-
toms [7]. Patients demonstrated mild to moderate motor
symptoms in both the first (M = 24.49, SD = 9.79), and
the second sample (M = 22.73, SD = 7.66), with no signif-
icant severity differences demonstrated between samples.
The spectrum of motor severity within the clinical group
is graphically depicted with an area graph in Figures 1 and
2, corresponding to the norming sample and the cross-
validation sample, respectively. Finally, all participants
were demonstrated to have a Mini-Mental Status Exami-
nation (MMSE) score of at least 27 at the time of testing.
The response time tasks used in this study started with an
instruction to watch a fixation point (asterisk) in the cen-
tre of the computer screen, while depressing the home key
(measuring 1.905 cm × 1.905 cm) in the centre of the
response console. For the 'uncued' task, participants were
not given any advance information concerning the loca-
tion of the upcoming stimulus. For the 'cued' task, an
arrow appeared in place of the fixation point (i.e. in the
center of the screen) for a period of 2 seconds, immedi-
ately following the disappearance of the fixation point,
Area graph depicting range of motor impairment in the nor-ming sample (40 patients, 40 contr ls)Figure 1
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on all trials. The visual stimulus to which the subject
responded was presented on the right or left side of the
monitor, at a random interval (between 500 and 1500
ms) following the fixation point ('uncued') or the arrow
('cued'). Participants responded to the stimulus by mov-
ing the index finger of their dominant hand from the
home key to a response key (measuring 1.905 cm × 1.905
cm) placed 3.175 cm to the left or right of the home key,
as directed by the stimulus placement on the screen. The
time measured between the onset of the visual stimulus
and a participant's movement from the home key was
defined as reaction time (RT), and the time measured
between a participant's lift from the home key and depres-
sion of the response key was defined as movement time
(MT). Each task consisted of 10 practice trials, and 40
experimental trials. A participant's RT and MT was com-
puted as the unit-weighted average of scores on the 'cued'
and 'uncued' choice response time tasks. This testing
apparatus is described in further detail by Johnson et al.
[8].
All patients involved in the study were asked to remain
drug-free overnight, and to delay taking their morning
anti-Parkinsonian medications until after the testing. To
avoid any confounding effects resulting from different lev-
els of caffeine intake among participants, all participants
were asked to have a normal caffeine-free breakfast prior
to testing. None of the participants reported any acute
physiological conditions that may have precluded them
from putting forth their best effort during the testing ses-
sion. All procedures and materials were approved by the
Health Sciences Research Ethics Board at the University of
Western Ontario.
Results
In the first sample (40 patients and 40 healthy partici-
pants), separate receiver operator characteristic (ROC)
curves were generated for the composite RT and MT
scores. The best prediction (i.e. the largest area under the
ROC curve) was achieved using the composite MT score.
The cutoff score was identified as the point on the curve
that maximized sensitivity, with a specificity of at least
70%. This cutoff score was determined to be 230 ms (i.e.
individuals with a MT of at least 230 ms were identified as
having PD). To control for the possibility that classifica-
tion success in the first sample was the result of a capital-
ization on sample-specific variability [9], this
classification strategy (i.e. the cutoff score identified from
the ROC within the first sample) was cross-validated in
the second sample (20 patients and 20 healthy
participants). Classification results and diagnostic efficacy
variables for both samples are presented in Table 1.
To identify the extent to which response time predicted
disease progression, correlations were computed between
the UPDRS and the aggregate RT and MT scores. As the
samples demonstrated no significant differences on the
UPDRS, correlations were computed across all data col-
lected in both samples. Both RT (r = 0.23, n.s.) and MT (r
= 0.59, p < 0.025) were positively correlated with the
UPDRS, suggesting that these response time tasks are
good predictors of the severity of Parkinsonian symp-
toms, particularly when considering the MT component
of response time.
Discussion
This study confirms previous research that has shown sig-
nificant movement time (MT) differences between PD
patients and healthy participants [5]. The results of the
present study also suggest that MT composites on biome-
chanically simple response time tasks demonstrate high
cross-validated sensitivity and specificity for 'unmedi-
cated' patients (i.e. patients that have been temporarily
withdrawn from their dopaminergic medications) – and
that these values may be higher than the demonstrated
sensitivity and specificity of the motor subtest employed
by Montgomery et al. [3,4].
Standardized objective test batteries will be diagnostically
useful in two general scenarios: (a) as an adjunct to the
physical examination performed by a specialist (to
improve diagnostic accuracy), and (b) as a standardized
preliminary screening tool, for situations in which a
movement disorders expert is unavailable for the physical
examination. The latter situation is more important than
Area graph depicting the range of motor impairment in the cross-validation sample (20 patients, 20 controls)Figure 2
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point of contact for these patients. Given the waiting
times to see a movement disorders specialist, patients that
are considered likely to have PD (based on a screening
measure) might be assigned a higher priority in their wait
for an initial appointment. This assumes, of course, that
primary care physicians will have access to the appropriate
motor performance testing devices – and while this is cur-
rently prohibitive from a logistical standpoint, it is tech-
nologically feasible for the simple tasks described herein
to be packaged in smaller (perhaps handheld), less expen-
sive devices.
A MT battery may also allow for the communication of
results in a "common metric" – without relying on subjec-
tive clinical judgments, thereby complementing other
clinical tools. Aside from its diagnostic utility, MT batter-
ies may also be useful in tracking a patient's progress as
he/she undergoes treatment. At present, motor evalua-
tions conducted during the clinical exam are the only
method for tracking change, and this is considerably more
qualitative than the MT measures described herein. Along
similar lines, MT batteries could make useful adjuncts to
clinical drug trial protocols, as they provide good quanti-
tative measures of motor skill that may be used to gauge
the effectiveness of the medication under study – in the
present study, MT was able to explain 34.81% of the vari-
ability in UPDRS motor scores.
It should, of course, be noted that the present research was
only used to separate PD patients from healthy partici-
pants, and so it has not been demonstrated to have any
differential diagnostic capabilities (e.g. distinguishing PD
from progressive supranuclear palsy). Future research in
this area should, therefore. investigate the differential
diagnostic power of response time batteries – it may be
that the MT battery administered in this study are detect-
ing a general 'impairment' factor, and is not useful as a
standalone instrument for the diagnosis of Parkinson's
disease. Extending the study base to include patients with
disorders such as progressive supranuclear palsy would
provide important information concerning appropriate
norming that may be done to maximize diagnostic utility.
At the very least, however, these results suggest that the
use of simple response time batteries may serve as a useful
adjunct to other clinical assessment batteries, and may
also open interesting avenues of exploration into the con-
sideration of the biological underpinnings of reaction
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Table 1: Classification results
Sample #1 (40 Patients, 40 Controls) Sample #2 (20 Patients, 20 Controls)
Dx by Neurologist Dx by Neurologist
PD Control PD Control
Predicted Dx PD 33 12 Predicted Dx PD 18 2
Control 7 28 Control 2 18
Sensitivity 82.5% Sensitivity 90.0%
Specificity 70.0% Specificity 90.0%Page 4 of 5
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